Cyclin-Dependent Kinase 4 and 6 Inhibitors as Breast Cancer Therapy: Research Progress and Prospects

Pharmaceutical Chemistry Journal - Cyclin-dependent kinases 4 and 6 (CDK4/6) are the core part of the cell cycle control machinery, which bind to cyclin D to regulate cell G1-S cycle conversion....     

Facile synthesis of chitosan membranes for visible-light-driven photocatalytic degradation of tetracycline hydrochloride

Due to the film-forming ability of polymers, a variety of photocatalytic membranes (PMs) based on polymers easily being separated and reused have been constructed for wastewater contaminant treatment. During their construction processes, chitosan (CS) as a bio-polymer with its distinct merits of abundant resources, low-cost and environmental-friendliness, as well as formability and ease of modification, has attracted great attention. However, the role of CS was mostly believed to be just a support or an adsorbent for fixing or dispersing photocatalysts. Whether CS possessed photocatalytic activity or not still remained vague. Herein, in this work, CS membranes (CSM) were facilely prepared for photocatalytic degradation of tetracycline hydrochloride (TC, a model organic pollutant) in aqueous solution, and its photocatalytic performance was investigated and compared with that of CSP (CS powder) and TiO₂-P25 (a commercially used photocatalyst). The results showed that the single-phased CSM exhibited a better visible light photocatalytic activity. After visible light irradiation for 60 minutes, the degradation efficiency of TC can reach above 90% when the CSM was used as a photocatalyst, while with the same irradiation time interval, less TC could be degraded over both CSP and TiO₂-P25. Through radical scavenging and EPR experiments, ˙O₂⁻ and h⁺ were found to be the main active oxygen species generated in the reaction system for TC degradation. After being washed with 2 wt% NaOH solution, the CSM revealed a good recyclability implying its potential for practical applications. This study would provide a certain theoretical and data basis for the future development of CS-based PMs and photocatalysts.

Chitosan membrane exhibited a good visible light photocatalytic activity over tetracycline hydrochloride degradation. The corresponding degradation mechanism was investigated as shown above.     

Intermediate dose cytarabine improves survival and relapse-free rate compared with standard-dose cytarabine as post-remission treatment for acute myeloid leukemia: A retrospection study

The exact dose of cytarabine still remain controversial for the management of patients with acute myeloid leukemia (AML) after complete remission (CR), but recent studies favor lower doses. This study aimed to investigate the toxic effects of single-intermediate dose (ID) cytarabine in patients with AML after achieving CR, compared with standard-dose cytarabine.In this retrospective study, AML patients who achieved CR after consolidation therapy before enrollment between 07/2008 and 05/2019 were included. All patients were divided into single-ID cytarabine and standard-dose cytarabine. The Kaplan-Meier method was used to compare overall survival (OS) and relapse-free time (RFS). Cox regression models were used to assess factors independently associated with OS and RFS. The toxic side effects of hematology and non-hematology were observed.52 patients were enrolled. There were 33 in ID group, 19 in Standard dose group. The 3-year RFS rate (40.4% vs 22.2%, P = .031) was better in the ID group than in the standard-dose group, while the 3-year OS rate was not different between the 2 groups (50.2% vs 27.8%, P = .074). Treatment stratage of ID cytarabine chemotherapy significantly improve the prognosis of AML regardless of patient age, risk grade, WBC count. There were no significant differences between the 2 groups in grade 3 to 4 bone marrow suppression, gastrointestinal symptoms, blood transfusion, infections.Patients with AML receiving ID cytarabine showed better survival and similar toxicity profiles compared with patients who received standard-dose cytarabine.     

血小板生成素受体激动剂在脐血移植中的应用

血小板生成素受体激动剂(TPORA)是一系列可以与血小板生成素(TPO)受体(c-mpD特异性结合并发挥作用的药物.而脐血移植(CBT)自开始应用于临床后,由于其具有来源丰富、获取方便、供者无风险、人类白细胞抗原(HLA)配型相合程度要求较低、移植物抗宿主病(GVHD)发生率低,并且程度轻等优点,现已广泛被应用于恶性血液病的治疗.笔者就TPORA的生物学特性及其应用于CBT的前景和风险作一总结.